Preparation and evaluation in vitro and in vivo of pristinamycin enteric-coated granules based on albumin nanoparticles

References

• Maskell JP, Sefton AM, Williams JD, et al. Comparative in-vitro activity of erythromycin, vancomycin and pristinamycin. Infection. 1988;6:365–370.
   Google Scholar
• Teng JC, Lingaratnam SM, Trubiano JA, et al. Oral pristinamycin for the treatment of resistant gram-positive infections in patients with cancer: evaluation of clinical outcomes. Int J Antimicrob Agents. 2016;5:391–396.
   Google Scholar
• Ng J, Gosbell IB. Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant staphylococcus aureus (mrsa) and other staphylococcus spp. J Antimicrob Chemother. 2006;55(6):1008–1012.
   Google Scholar
• Reid AB, Daffy Fau- Stanley Jr P, Stanley P Fau- Buising KL, et al. Use of pristinamycin for infections by gram-positive bacteria: clinical experience at an Australian hospital. Antimicrob Agents Chemother. 2010;54(9):3949–3952.
   Google Scholar
• Seto W, Lai C, Yuen R. Kucers’ the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic and antiviral drugs. 7th ed., Vol. 3, p. 4335-4344. Boca Raton, FL: CRC Press, 2018.
   Google Scholar
• Meng J, Feng R, Zheng G, et al. Improvement of pristinamycin i (pi) production in streptomyces pristinaespiralis by metabolic engineering approaches. Synth Syst Biotechnol. 2017;2(2):130–136.
   PubMedGoogle Scholar
• Grayson ML, Crowe SM, Mccarthy JS, et al. Kucers’ the use of antibiotics. Int J Antimicrob Agents. 2011;3:170.
   Google Scholar
• Mutton KJ, Andrew JH. In vitro activity of pristinamycin against methicillin-resistant staphylococcus aureus. Chemotherapy. 1983;3:218–224.
   Google Scholar
• Shimada Y, Deguchi T, Nakane K, et al. Macrolide resistance-associated 23s rRNA mutation in mycoplasma genitalium, Japan. Emerg Infect Dis. 2011;6:1148–1150.
   Google Scholar
• Read T, Jensen JS, Fairley CK, et al. Use of pristinamycin for macrolide-resistant mycoplasma genitalium infection. Emerg Infect Dis. 2018;2:328–335.
   Google Scholar
• Barber M, Waterworth PM. Antibacterial activity of lincomycin and pristinamycin: a comparison with erythromycin. Br Med J. 1964;2:603.
   PubMedGoogle Scholar
• Rehm SJ, Graham DR, Latha S, et al. Successful administration of quinupristin/dalfopristin in the outpatient setting. J Antimicrob Chemother. 2001;5:639–645.
   Google Scholar
• Valour F, Laurent F, Ferry T, et al. Pristinamycin in the treatment of MSSA bone and joint infection—authors’ response. J Antimicrob Chemother. 2016;71:3318.
   PubMedGoogle Scholar
• Norma F-H, Juan F, Daniel G-M. A fast and simple evaluation of the chemical reactivity properties of the pristinamycin family of antimicrobial peptides. Chem Phys Lett. 2020;739:137021.
   Google Scholar
• Goffic FL. Structure activity relationships in lincosamide and streptogramin antibiotics. J Antimicrob Chemother. 1985;16(suppl A):13–21.
   PubMedGoogle Scholar
• Koechlin C, Kempf JF, Jehl F, et al. Single oral dose pharmacokinetics of the two main components of pristinamycin in humans. J Antimicrob Chemother. 1990;4:651–656.
   Google Scholar
• Reissier S, Cattoir VA-O. Streptogramins for the treatment of infections caused by gram-positive pathogens. Expert Rev Anti-infect Ther. 2021;19(5):587–599.
   Google Scholar
• Barriere JC, Berthaud N, Beyer D, et al. Recent developments in streptogramin research. Curr Pharm Des. 1998;2:155–180.
   Google Scholar
• Jiang Y, Stenzel M. Drug delivery vehicles based on albumin–polymer conjugates. Macromol Biosci. 2016;6:791.
   Google Scholar
• Kianfar E. Protein nanoparticles in drug delivery: animal protein, plant proteins and protein cages, albumin nanoparticles. J Nanobiotechnology. 2021;1:159.
   Google Scholar
• Najahi-Missaoui W, Arnold RA-O, Cummings BS. Safe nanoparticles: are we there yet?
   Google Scholar
• Wang X, Mohammad IS, Fan L, et al. Delivery strategies of amphotericin b for invasive fungal infections. Acta Pharm Sin B. 2021;8:2585–2604.
   Google Scholar
• He W, Kapate N, Shields CWt, et al. Drug delivery to macrophages: a review of targeting drugs and drug carriers to macrophages for inflammatory diseases. Adv Drug Deliv Rev. 2020;165–166:15–40.
   PubMed Web of Science ®Google Scholar
• Le Goffic F. Structure activity relationships in lincosamide and streptogramin antibiotics. J Antimicrob Chemother. 1985;16:13–21.
   PubMedGoogle Scholar
• Wang Y, Xu S, Xiao Z, et al. Stiripentol enteric solid dispersion-loaded effervescent tablets: enhanced dissolution, stability, and absorption. AAPS PharmSciTech. 2022;5:141.
   Google Scholar
• Wolfgang M, Stranzinger S, Khinast JG. Ascertain a minimum coating thickness for acid protection of enteric coatings by means of optical coherence tomography. Int J Pharm. 2022;618:121–680.
   Google Scholar
• Zhao X, Sun L A, Ge M, et al. Preparation and pharmacokinetic evaluation of enteric-coated capsules filled with pristinamycin nanoparticles. Chinese J Pharmaceut. 2021;5:661–668.
   Google Scholar
• Pechere JC. Streptogramins. A unique class of antibiotics. Drugs. 1996;51:13–19.
   PubMedGoogle Scholar
• Bonfiglio G, Furneri PM. Novel streptogramin antibiotics. Expert Opin Investig Drugs. 2001;2:185–198.
   Google Scholar
• Paris JM, Barrière JC, Smith C, et al. The chemistry of pristinamycins. In: Lukacs G, Ohno M, editors. Recent progress in the chemical synthesis of antibiotics. Berlin, Heidelberg: Springer Berlin Heidelberg; 1990. p. 183–248.
   Google Scholar
• Lamichhane S, Lee S. Albumin nanoscience: homing nanotechnology enabling targeted drug delivery and therapy. Arch Pharm Res. 2020;1:118–133.
   Google Scholar
• Karimi M, Bahrami S, Ravari SB, et al. Albumin nanostructures as advanced drug delivery systems. Expert Opin Drug Deliv. 2016;13(11):1609–1623.
   Google Scholar
• Tawfeek HM, Abdellatif AAH, Dennison TJ, et al. Colonic delivery of indometacin loaded PGA-co-PDL microparticles coated with Eudragit l100-55 from fast disintegrating tablets. Int J Pharm. 2017;1:80–89.
   Google Scholar
• Wang XQ, Zhang Q. Ph-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs. Eur J Pharm Biopharm. 2012;2:219–229.
   Google Scholar
• Han M, Yu Q, Liu X, et al. Preparation and characterization of a novel aqueous dispersion for enteric coating of pantoprazole sodium pellets. Acta Pharm. 2018;4:441–455.
   Google Scholar
• Elsadek B, Kratz F. Impact of albumin on drug delivery–new applications on the horizon. J Control Release. 2012;1:4–28.
   Google Scholar
• Liu Y, Han Y, Fang T, et al. Turning weakness into strength: albumin nanoparticle-redirected amphotericin b biodistribution for reducing nephrotoxicity and enhancing antifungal activity. J Control Release. 2020;324:657–668.
   Google Scholar
• Wang X, Wang X, Wang M, et al. Probing adsorption behaviors of BSA onto chiral surfaces of nanoparticles. Small. 2018;16:e1703982.
   Google Scholar
• Abdellatif AAH, Zayed G, El-Bakry A, et al. Novel gold nanoparticles coated with somatostatin as a potential delivery system for targeting somatostatin receptors. Drug Dev Ind Pharm. 2016;11:1782–1791.
   Google Scholar
• Liang Z, Yang Z, Yuan H, et al. A protein@metal-organic framework nanocomposite for ph-triggered anticancer drug delivery. Dalton Trans. 2018;30:10223–10228.
   Google Scholar
• Aljohani ASMA, Ahmed AH, Rasheed Z, et al. Gold-nanoparticle-conjugated citrate inhibits tumor necrosis factor-α expression via suppression of nuclear factor kappa b (nf-κb) activation in breast cancer cells. J Biomed Nanotechnol. 2022;2:581–588.
   Google Scholar
• Abdellatif AAH, El-Telbany DFA, Zayed G, et al. Hydrogel containing peg-coated fluconazole nanoparticles with enhanced solubility and antifungal activity. J Pharmaceut Innov. 2019;2:112–122.
   Google Scholar
• Abdellatif AAH, Ibrahim MA, Amin MA, et al. Cetuximab conjugated with octreotide and entrapped calcium alginate-beads for targeting somatostatin receptors. Sci Rep. 2020;1:4736.
   Google Scholar
• Li P, Hao J, Li H, et al. Development of an enteric nanoparticle of marine sulfated polysaccharide propylene glycol alginate sodium sulfate for oral administration: formulation design, pharmacokinetics and efficacy. J Pharm Pharmacol. 2018;6:740–748.
   Google Scholar
• SinghGill SVL. Pollen grains as a novel microcarrier for oral delivery of proteins. Int J Pharm. 2018;1(2):352–359.
   Google Scholar
• Mao Z, Li J, Huang W, et al. Preparation of poly(lactic acid)/graphene oxide nanofiber membranes with different structures by electrospinning for drug delivery. RSC Adv. 2018;30:16619–16625.
   Google Scholar
• Reissier S, Cattoir V. Streptogramins for the treatment of infections caused by gram-positive pathogens. Expert Rev Anti Infect Ther. 2021;5:587–599.
   Google Scholar
• Brittain DC. Erythromycin. Med Clin North Am. 1987;6:1147–1154.
   Google Scholar
• Polson JE. Hepatotoxicity due to antibiotics. Clinics Liver Dis. 2007;3:549–561.
   Google Scholar
• Mohi-Ud-Din R, Mir R, Sawhney G, et al. Possible pathways of hepatotoxicity caused by chemical agents. Curr Drug Metab. 2019;11:867–879.
   Google Scholar
• Bernard P, Chosidow O, Vaillant L, et al. Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial. BMJ. 2002;7369:864.
   Google Scholar
• Kresnamurti A, Rakhma D, Damayanti A, et al. AST/ALT levels, MDA, and liver histopathology of echinometra mathaei ethanol extract on paracetamol-induced hepatotoxicity in rats. J Basic Clin Physiol Pharmacol. 2021;4:511–516.
   Google Scholar